ArticleCureus2025
Diverticular Stricture and Hepatic Abscess Formation During Tirzepatide Therapy for Obesity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, is increasingly used worldwide for weight loss and glycaemic control but is associated with gastrointestinal side effects. We hereby present a case of a complicated diverticulitis with hepatic abscesses in a patient with pre-existing asymptomatic diverticular disease on tirzepatide. The patient, a 53-year-old man, developed severe sepsis and multi-organ dysfunction following rapid 25 kg weight loss. Imaging revealed sigmoid stricture, obstructive diverticulitis, and liver abscesses. Proposed mechanisms include reduced colonic motility, altered bile flow, and microbiota changes induced by tirzepatide, exacerbating diverticular disease and promoting bacterial translocation. This case highlights the need for clinical vigilance in patients with known or incidental diverticular disease receiving GLP-1 based therapies. Further research is warranted to assess whether routine monitoring should be implemented in this potentially high-risk subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.